Philip Morris International Inc. (NYSE / Euronext Paris: PM) announces that it has closed today following a positive vote from shareholders of Medicago Inc. ("Medicago") the second tranche of its previously announced private placement of common shares in Medicago (the "Offering") with the acquisition of CAD $11.18 million of common shares of Medicago. Each common share was issued at a price of CAD $0.65 per share.

As part of the Offering, Philip Morris Investments B.V. ("PM Investments"), a wholly-owned indirect subsidiary of PMI, acquired ownership of an aggregate of 34,550,000 common shares of which 11,200,000 common shares were acquired as part of the second tranche closing. All common shares were acquired pursuant to the "minimum amount investment" prospectus exemption contained in section 2.10 of Regulation 45-106 regarding Prospectus and Registration Exemptions (Québec). The 17,200,000 common shares represent approximately 6.98% of the issued and outstanding common shares of Medicago when calculated after giving effect to the Offering on a non-fully diluted basis. Pursuant to this transaction, the holding of PM Investments in Medicago consists of 98,608,800 common shares representing 40% of all of the issued and outstanding common shares of Medicago when calculated after giving effect to the Offering on a non-fully diluted basis.

Based on the total number of common shares issued and outstanding, described in the Management Proxy Circular dated November 11, 2011, and filed on SEDAR by Medicago in connection with the Offering, PMI remains the largest shareholder of Medicago after the Offering.

This most recent acquisition of common shares was made for investment purposes. PMI may, subject to market conditions and in accordance with applicable securities laws, make additional investments in, or dispositions of, securities of Medicago, including additional purchases of Medicago common shares.

Philip Morris International Inc.

Philip Morris International Inc. (PMI) is the leading international tobacco company, with seven of the world's top 15 international brands, including Marlboro, the number one cigarette brand worldwide. PMI's products are sold in approximately 180 countries. In 2010, the company held an estimated 16.0% share of the total international cigarette market outside of the U.S., or 27.6% excluding the People's Republic of China and the U.S. For more information, see www.pmi.com.

Investor Relations:
New York: +1 917-663-2233
Lausanne: +41 (0)58 242 4666
or
Media:
Lausanne: +41 (0)58 242 4500